We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cyprotex | LSE:CRX | London | Ordinary Share | GB00BP25RZ14 | ORD £0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 160.50 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCRX
RNS Number : 4645A
Cyprotex PLC
22 December 2014
Cyprotex PLC
("Cyprotex" or "the Company")
Director dealing
The Company received notification that Ralph Stephen Harris, Non-executive Director of the Company, acquired 25,000 ordinary shares in the Company on 19 December 2014 at a price of 42.5 pence per share. As a result of this purchase Mr. Harris has a beneficial interest in 235,514 ordinary shares in the Company representing approximately 1.05 per cent. of the Company's total voting rights.
Cyprotex PLC Tel : +44 (0)1625 505 100 Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel ir@cyprotex.com www.cyprotex.com N + 1 Singer (NOMAD and broker to Tel : +44 (0)20 Cyprotex) 7496 3000 Shaun Dobson shaun.dobson@n1singer.com Jen Boorer jen.boorer@n1singer.com www.nplus1singer.com
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSPGGMUPUPCGPP
1 Year Cyprotex Chart |
1 Month Cyprotex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions